Vancouver, British Columbia – On November 18, 2026, Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF), a biotechnology company specializing in diagnostic and prognostic tests based on three-dimensional telomere analysis, announced it has signed a term sheet dated August 20, 2026. This term sheet provides Telo Genomics with an option to acquire an exclusive worldwide commercial license from the University of Manitoba and Technion Research and Development Foundation Ltd. for an artificial intelligence (AI) method and system designed to automate the detection of low-concentration malignant cells in biological samples.
The contemplated license, subject to negotiation and execution of a definitive agreement, would grant Telo Genomics exclusive rights to make, use, sell, and import products and processes related to identifying, quantifying, and analyzing cancer cells from human biological samples. These applications include cancer screening, clinical diagnosis, treatment selection, and disease monitoring, encompassing products that may receive regulatory approval from agencies such as the FDA, EMA, and Health Canada.
The AI technology at the core of this agreement is engineered to automatically identify rare malignant cells, a critical capability for liquid biopsy minimal residual disease (MRD) testing where cancer cells may be present at extremely low frequencies. If the definitive license agreement is executed, Telo Genomics would obtain exclusive rights to this jointly developed AI technology, which is intended to support a more reproducible and scalable workflow for detecting circulating tumor cells prior to profiling with TeloView®, the company’s proprietary three-dimensional telomere analysis platform.
John Farlinger, Chief Executive Officer and Chairman of Telo Genomics, emphasized the strategic significance of the term sheet, stating, "This term sheet is a natural extension of the scientific collaboration that built Telo Genomics. Our platform already combines highly sensitive detection of circulating tumor cells with single-cell 3D telomere analysis. Exercising the option and entering into a definitive license agreement for this AI detection method, developed by the University of Manitoba and Technion, could help make that workflow faster, more reproducible and commercially scalable as we advance our multiple myeloma program and evaluate additional oncology applications."
Farlinger further highlighted the clinical importance of automating cancer cell detection: "Detecting the right cell is the first step in any liquid-biopsy assay. Automating that step with AI reduces operator variability and supports the sensitivity required for MRD. Pairing automated cell identification with 3D telomere profiling is consistent with our goal of giving clinicians both a count of residual disease and a readout of its biological aggressiveness."
The term sheet covers a worldwide territory and a field of use focused on the identification, quantification, and analysis of cancer cells from human biological samples. It provides Telo Genomics an option for an exclusive license within this field, but no license rights have been granted at this stage. Any license grant remains contingent upon negotiation and execution of a definitive license agreement, and there is no assurance such an agreement will be finalized.
Telo Genomics is recognized for pioneering a comprehensive telomere platform with applications in oncology and neurological diseases. Its technologies include liquid biopsies that offer less invasive and more reproducible alternatives to traditional diagnostic methods. The company’s expertise integrates quantitative 3D telomere analysis with molecular biology and AI to detect disease-associated genetic instability. Its lead product, Telo-MM, targets multiple myeloma, a severe blood cancer, and the company’s technology has been validated in over 190 peer-reviewed publications and more than 30 clinical studies involving upwards of 3,000 patients.
The University of Manitoba, established in 1877 as Western Canada’s first university, is a major research institution based in Winnipeg. It houses the Max Rady College of Medicine and maintains a broad research portfolio spanning health sciences, life sciences, and technology translation. The university commercializes its research through its Partnerships and Knowledge Mobilization office.
This development marks a significant potential advancement in Telo Genomics’ liquid biopsy platform, leveraging AI to enhance the detection and analysis of rare cancer cells, thereby supporting improved clinical outcomes in oncology.
Telo Genomics Secures Option for Exclusive Global License to AI Technology Targeting Rare Cancer Cell Detection Telo Genomics has signed a term sheet granting it an option to obtain an exclusive worldwide commercial license for an AI-based method that automates detection of rare malignant cells in biological samples. The agreemen... Read the full IIPLA article: https://iipla.org/news/telo-genomics-secures-option-for-exclusive-global-license-to-ai-technology-targeting-rare-cancer-cell-detection